Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cerebrospinal Fluid01:21

Cerebrospinal Fluid

4.9K
Cerebrospinal fluid (CSF) is a colorless liquid that flows around the brain and the spinal cord, playing a vital role in the protection, support, and overall function of the central nervous system (CNS). CSF production, circulation, and absorption are tightly regulated processes essential for the brain and spinal cord to function properly.
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain....
4.9K
Complement System01:27

Complement System

9.3K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.

European journal of immunology·2026
Same author

Dysregulation of complement at the synapse in P301S mice and human tauopathies.

Acta neuropathologica communications·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries.

Therapeutic advances in neurological disorders·2026
Same author

A framework for blood biomarker discovery in MS.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Related Experiment Video

Updated: Jan 4, 2026

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.5K

Cerebrospinal fluid complement system biomarkers in demyelinating disease.

Wioleta Milena Zelek1, Dina Fathalla1, Angharad Morgan1

  • 1Systems Immunity University Research Institute, Cardiff University, Cardiff, UK.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|November 9, 2019
PubMed
Summary

Cerebrospinal fluid complement biomarkers can help differentiate multiple sclerosis (MS) from neuromyelitis optica spectrum disorder (NMOSD). Specific proteins in CSF distinguish these demyelinating diseases, aiding diagnosis.

Keywords:
Multiple sclerosisbiomarkerscerebrospinal fluidcomplementneuromyelitis optica

More Related Videos

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

11.5K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.2K

Related Experiment Videos

Last Updated: Jan 4, 2026

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.5K
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

11.5K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.2K

Area of Science:

  • Neuroimmunology
  • Biomarker Discovery
  • Complement System Research

Background:

  • Multiple sclerosis (MS) diagnosis can be challenging due to overlap with other demyelinating diseases like neuromyelitis optica spectrum disorder (NMOSD).
  • Previous research identified plasma complement biomarkers distinguishing NMOSD from MS.
  • This study investigates cerebrospinal fluid (CSF) complement biomarkers for NMOSD differentiation.

Purpose of the Study:

  • To assess CSF complement proteins for distinguishing NMOSD from MS and clinically isolated syndrome (CIS).
  • To identify specific complement biomarkers in CSF that can aid in diagnosing NMOSD.

Main Methods:

  • CSF samples from patients with MS, CIS, NMOSD, and controls were analyzed.
  • Quantification of various complement proteins, regulators, and activation products using ELISA.
  • Results were normalized to CSF total protein concentration.

Main Results:

  • Elevated levels of C4, C1 Inhibitor (C1INH), and Properdin were observed in MS CSF compared to controls.
  • Increased levels of Terminal Complement Complex (TCC), iC3b, Factor I (FI), and FH-Related Proteins 1, 2 and 5 (FHR125) were found in CIS CSF.
  • Most complement biomarkers were elevated in NMOSD CSF, with notable exceptions.
  • A statistical model using six analytes (C3, C9, Factor B (FB), C1q, FI, Properdin) and demographic data effectively differentiated MS from NMOSD.

Conclusions:

  • CSF complement profiles differ across MS, CIS, and NMOSD.
  • Specific CSF complement biomarkers show potential for differentiating NMOSD from MS and CIS.
  • A combination of complement analytes and demographic factors offers a robust method for distinguishing MS from NMOSD.